GSK Says No Basis For Fraud Claims In Zofran MDL
GlaxoSmithKline plc asked a Massachusetts federal judge on Thursday to dismiss fraud-based claims from multidistrict litigation connecting the anti-nausea drug Zofran to birth defects, arguing that the master complaint is devoid...To view the full article, register now.
Already a subscriber? Click here to view full article